PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.43%
R&D growth while TRVN reduces spending. John Neff would investigate strategic advantage.
12.93%
G&A growth 1.1-1.25x TRVN's 11.29%. Bill Ackman would demand evidence of necessary spending.
No Data
No Data available this quarter, please select a different quarter.
5.37%
Other expenses growth less than half of TRVN's 198.49%. David Dodd would verify if advantage is sustainable.
14.34%
Operating expenses growth while TRVN reduces costs. John Neff would investigate differences.
14.34%
Total costs growth while TRVN reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
5.37%
D&A growth less than half of TRVN's 19.72%. David Dodd would verify if efficiency is sustainable.
-16.61%
EBITDA decline while TRVN shows 43.92% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-14.34%
Operating income decline while TRVN shows 41.47% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-295.23%
Other expenses reduction while TRVN shows 198.49% growth. Joel Greenblatt would examine advantage.
-20.40%
Pre-tax income decline while TRVN shows 42.62% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-20.40%
Net income decline while TRVN shows 42.62% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-19.61%
EPS decline while TRVN shows 45.70% growth. Joel Greenblatt would examine position.
-20.61%
Diluted EPS decline while TRVN shows 45.70% growth. Joel Greenblatt would examine position.
0.76%
Share count reduction exceeding 1.5x TRVN's 5.65%. David Dodd would verify capital allocation.
No Data
No Data available this quarter, please select a different quarter.